HCPLive Network

Including Newer Biomarkers in Testing Improves Death Prediction in Chronic Kidney Disease

Though patients with chronic kidney disease (CKD) have variable risks of death, the population risk prediction tools that are currently available perform poorly. 
 
To establish more satisfactory prediction models, Adeera Levin, MD, and colleagues from the Division of Nephrology of the Department of Medicine of the University of British Columbia undertook the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT) — a large, prospective cohort study that began in 2008 — and reported their findings at Kidney Week 2013, the American Society of Nephrology's annual  meeting held November 5-10, 2013, in Atlanta, GA.
 
In that study, 2,544 CKD patients referred from 25 rural, urban, academic, and non-academic centers throughout Canada underwent baseline newer biomarker (NMB) tests, which included asymmetric dimethylarginine (ADMA), high sensitivity C-reactive protein (hsCRP), interleukin 6, N-terminal pro-brain natriuretic peptide (NTproBNP), troponin I, transforming growth factor beta 1 (TGFβ1), cystatin C, and fibroblast growth factor (FGF23). The mean age of the cohort was 68 years old, while the median estimated glomerular filtration rate (eGFR) was 28ml/min/1.73m2. According to the researchers, 48% of patients had diabetes,  and 15.5% died during the 3-year follow-up.
 
Patients were followed for 3 years at 6-month intervals and annually monitored for traditional biomarkers, such as eGFR, urine albumin creatinine ratio (uACR), hemoglobin (Hgb), and phosphate and albumin. The researchers also performed the aforementioned NMB tests after collecting blood and urine samples on schedule.
 
To investigate whether including NBMs improve the prediction of death risk in CKD patients to a greater extent than conventional clinical, demographic, and laboratory predictors, the researchers compared discrimination (C statistic) and classification (NRI) of proportional hazard models based on conventional markers versus a combination of conventional and NBM markers.
 
After adjusting for base predictors, they found that the biomarker NTproBNP was the best predictor of mortality (NRI=8.9; 95% confidence interval [CI]: 3.3-17.4), followed by hsCRP (NRI=4.5; 95% CI: 1.3-9.6) and FGF23 (NRI=3.1; 95% CI: 0.4-11.4).
 
While the authors found that including NBMs in risk prediction models significantly improves the precision of death prediction in CKD patients, they noted that their approach needs to be validated with further testing.
 
The authors disclosed support from Ortho Janssen.


Further Reading
Research indicates that patients with type 2 diabetics mellitus and low testosterone levels are 6 times more likely than those with normal testosterone levels to have increased carotid artery intima media thickness (CIMT) and decreased endothelial function.
Distal radius fracture—also called a wrist fracture by patients—is common. Its incidence is expected to increase in the next 20 years, since our population is aging and the risk of this specific fracture increases in patients with metabolic disorders, including osteoporosis. However, the health care community has yet to reach a consensus regarding indications for surgery, and there is insufficient data to identify a preferred operative technique.
Team-based feedback has the potential to improve surgeons’ relationships with coworkers and patients. The clinical implication: using such feedback to improve less-than-optimal behaviors could increase practice reimbursement under the “pay-for-professionalism” system.
More Reading
Research indicates that patients with type 2 diabetics mellitus and low testosterone levels are 6 times more likely than those with normal testosterone levels to have increased carotid artery intima media thickness (CIMT) and decreased endothelial function.